医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

PBM Capital Group has completed the sale of a majority interest in Breas Medical Group to Fosun Pharma

2017年03月17日 PM09:00
このエントリーをはてなブックマークに追加


 

CHARLOTTESVILLE, Va.

PBM Capital Group has completed the sale of a majority interest in Breas Medical Group (“Breas”) to Fosun Pharma (“Fosun”), a leading healthcare company in China. Fosun is publicly listed on the Hong Kong and Shanghai stock exchanges. PBM Capital will remain a partner with Fosun and both parties will work together with management to expand Breas.

“Fosun adds scale and will further strengthen Breas’ presence in Asia, a high growth market,” says Damian deGoa, PBM Capital Managing Director. “With its 25-year history in Europe, rapid growth in the United States, and future expansion in China, Breas will have a strong presence in all major global markets. The prevalence of respiratory conditions like COPD and sleep apnea, the transition of healthcare from the hospital to the home, business development opportunities, and the upcoming launch of Breas’ new ventilation and CPAP products will accelerate future growth.”

Breas is a leading developer, manufacturer, and distributor of homecare ventilation and sleep apnea devices. Breas is headquartered in Gothenburg, Sweden, and has 150 employees in multiple locations around the world.

PBM Capital first invested in this segment as a venture investor in Human Design Medical. Then PBM Capital acquired Breas Medical AB from GE Healthcare. PBM Capital made a subsequent acquisition in the United Kingdom of B&D Electromedical. The three companies, Breas Medical AB, B&D Electromedical, and Human Design Medical, are all part of the Breas Medical Group.

About PBM Capital Group

PBM Capital is a healthcare focused private investment group. PBM Capital looks for opportunities to use its entrepreneurial and operational experience to make high growth pharmaceutical, molecular diagnostic, gene therapy, life science, health/wellness, and consumer product investments. PBM Capital portfolio companies include Dova Pharmaceuticals, Avexis (NASDAQ: AVXS), Verrica Pharmaceuticals, Xalud Therapeutics, Quantapore, Archer Dx, and PBM Pharmaceuticals.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170317005103/en/

CONTACT

PBM Capital Group
Sean Stalfort, 434-980-8104
sstalfort@pbmcap.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 新研究调查Masimo SpHb®在术后红细胞(RBC)输血最佳实践中的功用
  • 宝洁公司收购德国达姆施塔特默克集团的消费者健康业务
  • MOLOGEN AG: Collaboration with licensing partner ONCOLOGIE gains momentum
  • Vaxart Announces $5 Million Inavir® Revenue Milestone
  • 和铂医药与科伦博泰开展全球合作,共同开发多个创新全人源抗体药物